Monday, July 25, 2011

New Year Highs on “Stock Pick” Aspire International (APIT):  Our original prediction that APIT would begin a huge move higher was a few months early, but our conviction never wavered.  Over and over again we repeated our belief that APIT was going to be one of our biggest winners ever, especially whenever the stock has a dip.  The last selloff about two weeks ago represented the best time to buy APIT we had ever seen.  Now, APIT is practically making a new year high every day and at press time was trading at .545 per share up 65% from our original profile price of .33.  The Green Baron Report remains extremely bullish on the stock, and we believe APIT will soon issue financial results that support a much higher price.

News Issued Today on “Stock Alert” SSIE - SunSi Engages The Investor Relations Group - Will Initiate Investor and Media Outreach Program to Build Company Awareness – SSIE traded at $3.90 this morning up over 16.4% since our report issued a month ago on Tuesday, June 21.  Today’s news certainly indicates its intention to build awareness as it plans to transition to the AMEX exchange.  See entire press release at:

http://finance.yahoo.com/news/SunSi-Engages...

 

“Stock Pick of the Year” Update

Nuvilex, Inc.

(OTCQB: NVLX)

News Issued Today!

Nuvilex’s Successes Featured in Major Industry Publications

Monday, July 11: Publisher Konrad Kuhn Projects $1.00 – $2.00 Intermediate Target Price

It is clearer to us than ever that Nuvilex (NVLX) is headed on a path to success just like Aspire International (APIT) and SunSi Energies (SSIE).  It is surprising to us that NVLX is currently trading near our original profile price of .059 per share, but to us only represents an incredible opportunity to buy shares at a low price.  Remember, we still believe the stock will be above .25 by year end.

Today’s news points out the significance behind its flagship live-cell encapsulation technology platform, and how the news is just starting to spread throughout the world in publications.  We urge all members to carefully read this news and build an understanding how important this platform is to the future of medicine.  See full announcement below:

Press Release Source: Nuvilex, Inc. On Monday July 25, 2011, 10:37 am EDT

SCOTTSDALE, Ariz.--(BUSINESS WIRE)-- Nuvilex, Inc. (OTCQB: NVLX) announced today successes of its flagship live-cell encapsulation technology platform, Cell In A Box®, have recently been featured in major industry publications.

While highlighting the success of the Company’s Cell In a Box® platform, BioSpectrum Asia cited and quoted Nuvilex’s SG Austria on multiple occasions recently. The publication cited the benefits of using encapsulated live-cell therapy, as the encapsulated cells are able to activate the chemotherapeutic agent in the exact location and on a targeted basis at the tumor site, thereby allowing the chemotherapy dosage to be reduced. Therefore, patients benefit from the absence of typical chemotherapeutic toxicity as a result of the concurrent use of live-cell therapy.

BioSpectrum Asia also featured and quoted SG Austria management on the topic of how the live-cell technology approach in concert with stem cells will bring about a paradigm shift in disease treatment.

“Encapsulated stem cells have been discussed to hold potential to treat a wide number of diseases including cancer, stroke, cardiovascular diseases, genetic and metabolic diseases such as enzyme deficiencies, autoimmune diseases, bone and cartilage diseases and pain relief,” said Dr. Brian Salmons, President and CEO of SG Austria.

In the most recent edition of BioCentury, a key publication for C-level health care leaders, managers, and scientists, the Company’s most recent and successful preclinical study on breast cancer was featured. Using the Nuvilex live-cell encapsulation technology and a combination of two anticancer drugs, there were clear breast tumor successes. One of the most important findings discussed included the exciting proof of concept confirmation as use of either drug alone in the two different breast cancer models was not as effective as the combination of both which was more than additive.

Dr. Ryan stated, “This is the second clear success of the use of live-cell encapsulation in cancer treatment applications, pancreatic and now breast cancer. When we are able to ramp up operations, additional uses already planned will be initiated.” These successes are critical groundwork for future applications and dramatically increase the value of Nuvilex’s live-cell encapsulation therapy.

About Nuvilex, Inc.

Nuvilex, Inc. (OTCQB: NVLX) is an innovative biotechnology and natural products company. Nuvilex’s leading oncology offerings under development include a late stage treatment for advanced pancreatic cancer and early stage breast cancer treatment using the company’s industry-leading live-cell encapsulation technology.

The pancreatic cancer treatment is being readied for additional clinical trials and significant advances are in progress with the live-cell encapsulation technology. Current natural products include flagship Gluten-Free Cinnergen™ and others to enhance a healthy lifestyle. Additional offerings include products designed for cosmetic use, flu treatment, and the use of heavy-metal-free tattoo inks. Future developments are planned for Citroxin™ and Oraphyte™, Nuvilex’s antimicrobial and antinematodal agents.

Safe Harbor Statement

This information may contain forward-looking statements involving risks and uncertainties. Results, events and performances could vary from those contemplated. These risks and uncertainties which may cause actual results, expressed or implied, to differ from predicted outcomes including product demand, market competition, and Nuvilex’s ability to meet current or future plans. Investors should study and understand all risks before making investment decisions. Readers are recommended not to place undue reliance on forward-looking statements or information. Nuvilex is not obliged to publicly release revisions to any forward-looking statement, reflect events or circumstances afterward, or to disclose unanticipated occurrences, except as required under applicable laws.

Contact:

Investor Relations Contact:
Marmel Communications, LLC
Marlin Molinaro, 702-434-8692
mmolinarofc@aol.com